THER-26. PHARMACOKINETIC AND UPDATED OUTCOME DATA FROM PNOC-002: A SAFETY STUDY OF VEMURAFENIB, AN ORAL INHIBITOR OF BRAFV600E, IN CHILDREN WITH RECURRENT/REFRACTORY BRAFV600E MUTANT BRAIN TUMORS

BACKGROUND: Vemurafenib is an orally administered inhibitor of BRAF-V600E kinase approved for the treatment of BRAF-V600E mutated melanoma. We have previously presented favorable radiographic response and safety data for vemurafenib in children with BRAF-V600E mutated brain tumors and report here an...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Neuro Oncol
Asıl Yazarlar: Nicolaides, Theodore, Margol, Ashley, Gajjar, Amar, Goldman, Stewart, Gauvain, Karen, Kilburn, Lindsay, Nazemi, Kellie, Minturn, Jane, Leary, Sarah, Whipple, Nicholas, Gururangan, Sridharan, Crawford, John, Long-Boyle, Janel, Wang, Hechuan, Ivaturi, Vijay, Aboian, Mariam, Molinaro, Annette, Mueller, Sabine, Prados, Michael
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2019
Konular:
Translational Therapeutics
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6477532/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz036.231
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller